PrimeRFP - AI-Powered RFP Solutions
PrimeRFP SCOUT · Federal Contract Recompete Brief

W58P0522F0001 — PURCHASE OF A TOTAL OF 614,000 DOSES OF COMBINATION MONOCLONAL ANTIBODY.

PURCHASE OF A TOTAL OF 614,000 DOSES OF COMBINATION MONOCLONAL ANTIBODY. is a federal award for Department of Defense (DOD) held by ELI LILLY AND COMPANY. Estimated value $1.3B ($1.3B obligated). Current period of performance ends Feb 15, 2022 (potential Dec 31, 2022). Place of performance: INDIANAPOLIS, IN.

$1.3B
Estimated Value
Feb 15, 2022
PoP End / Expires
More in SCOUT — score this to your firm →See related expiring contracts →

Analysis

Public

ELI LILLY AND COMPANY holds $282K across 4 federal awards, concentrated at Department of Veterans Affairs (VA). PoP ended Feb 15, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Contract facts

Federal
Contract numberW58P0522F0001
AgencyDepartment of Defense (DOD)
IncumbentELI LILLY AND COMPANY
UEIUHHVNTY54K68
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDVW911QY21D0012
Place of performanceINDIANAPOLIS, IN
PoP end (current)Feb 15, 2022
PoP end (w/ options)Dec 31, 2022
Obligated$1.3B

PURCHASE OF A TOTAL OF 614,000 DOSES OF COMBINATION MONOCLONAL ANTIBODY.

Recompete timing

Public
● Past PoP end (1637 days ago)

Current PoP ended Feb 15, 2022 (1637 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Track recompete timing in SCOUT →

Incumbent footprint

Public record

ELI LILLY AND COMPANY — $282K obligated across 4 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)
Department of Veterans Affairs (VA)$282K · 100% of firm total
Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Score this to your firm — $90 Pilot →

Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. 90 days · $90 · no annual contract · cancel anytime

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open ELI LILLY AND COMPANY’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract W58P0522F0001?

W58P0522F0001 (PURCHASE OF A TOTAL OF 614,000 DOSES OF COMBINATION MONOCLONAL ANTIBODY.) is a Department of Defense (DOD) award with an estimated value of $1.3B, currently held by ELI LILLY AND COMPANY. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on W58P0522F0001?

ELI LILLY AND COMPANY is the incumbent with $282K across 4 related awards in SCOUT’s public footprint. The current period of performance ends Feb 15, 2022.

When does W58P0522F0001 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 15, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/W911QY21D0012-W58P0522F0001